Whilst the prevalence of obesity continues to increase at an alarming rate worldwide, the
personal and economic burden of obesity-related complications becomes ever more …

Diabetes is one of the major diseases worldwide and is the third leading cause of death in
the United States. Anti-diabetic drugs are used in the treatment of diabetes mellitus to control …

Obesity is a public health epidemic in the United States, with implications for patients across
many organ systems. Despite improvements in understanding the pathophysiology and …

In early childhood, individuals with Prader‐Willi syndrome (PWS) experience excess weight
gain and severe hyperphagia with food compulsivity, which often leads to early onset morbid …

The glucagon-like peptide-1 receptor (GLP-1R) agonist liraglutide is approved for the
treatment of obesity; however, there is still much to be learned regarding the neuronal sites …

Liraglutide is a new hypoglycemic drug. The previous studies have shown that liraglutide
can improve the renal outcomes of patients with type 2 diabetes. Recently, it was approved …

Introduction: The prevalence of obesity is increasing worldwide and associated conditions,
particularly type 2 diabetes mellitus (T2DM), also show increasing prevalence. Lifestyle …

Non-alcoholic fatty liver disease (NAFLD) is a common comorbidity in individuals with
obesity. Although multiple pharmacotherapeutics are in development, currently there are …

The continued global growth in the prevalence of obesity coupled with the limited number of
efficacious and safe treatment options elevates the importance of innovative pharmaceutical …

Obesity is a major factor in contemporary clinical practice in nephrology. Obesity accelerates
the progression of both diabetic and non-diabetic chronic kidney disease and, in renal …